|
医学院
导师姓名： 肖波 性 别： 男 特 称： 职 称： 教授 学 位： 工学博士学位 属 性： 专职 电子邮件： bxiao@uestc.edu.cn 学术经历： 2002年9月–2006年7月，欧博注册西南大学生物工程，学士 2006年9月–2008年7月，华中科技大学生化及分子生物学，欧博代理硕士 2008年9月–2011年7月，华中科技大学生物医学工程，博士（导师：张胜民 教授） 2011年9月–2016年9月，欧博官网美国佐治亚州立大学生物医学科学研究院/美国心脏协会，博士后（合作导师：Didier Merlin 教授） 2019年3月–2020年3月，美国佐治亚州立大学生物医学科学研究院，欧博娱乐访问学者（合作导师：Didier Merlin 教授） 个人简介： 肖波，教授，博士生导师。先后入选国家级青年人才计划、药学领域“全球前2%顶尖科学家”和“全球前10万顶尖科学家”等，欧博allbet电子科技大学医学院附属四川省人民医院药学部教授，主要围绕口服药物递送系统的应用基础与临床转化开展研究工作。近年来，先后以唯一或最后通讯作者身份在Gastroenterology（“胃肠道与肝病学”领域排名第一期刊）、Advanced Materials、ACS nano、Advanced Drug Delivery Reviews、Biomaterials、Molecular Therapy、Acta Pharmaceutica Sinica B、Journal of Controlled Release、Research、Small和Theranostics等学术期刊上发表学术论文60余篇；申请美国专利2项（授权1项）、中国专利10余项（授权5项）。现为Research和Chinese Chemical Letters青年编委会委员，曾多次应邀为Nature Biomedical Engineering, Gastroenterology, Nature Communications, Science Advances, Advanced Materials, Advanced Functional Materials, Nano Today, PNAS, ACS nano, Advanced Science, Biomaterials, Journal of Controlled Release, Small, Theranostics, Clinical Cancer Research, Chemical Communications和Biomacromolecules等杂志审稿。 科研项目： 1. 国家级高层次青年人才项目，“生物与新医药技术” 2. 国家自然科学基金面上项目，“温和光热调控炎症微环境提高口服纳米药物治疗溃疡性结肠炎效率的机制研究” 3. 国家自然科学基金面上项目，“口服靶向纳米粒子介导CD98沉默提高结肠癌化疗敏感性及其分子机制研究” 4. 国家自然科学基金青年项目，“靶向共载CD98-siRNA和姜黄素纳米粒子/水凝胶系统的构建及其口服协同治疗溃疡性结肠炎的机制研究” 5. 美国心脏协会（American Heart Association）博士后研究基金，“Nanoparticles: Therapeutic Approach in Atherosclerosis” 研究成果： 1. Ya Ma, Shuangquan Gou, Zhenhua Zhu, Jianfeng Sun, Mohammad-Ali Shahbazi, Tieyan Si, Cheng Xu, Jinlong Ru, Xiaoxiao Shi, Rui L. Reis, Subhas C. Kundu, Bowen Ke*, Guangjun Nie*, and Bo Xiao*. Transient mild photothermia improves therapeutic performance of oral nanomedicines with enhanced accumulation in the colitis mucosa. Advanced Materials 2023, Just Accepted. (IF = 29.4) 2. Bo Xiao*, Yuqi Liang*, Lingshuang Wang, Zhan Zhang, Libin Qiu, Haiting Xu, Sean Carr, Xiaoxiao Shi, Rui L. Reis, Subhas C. Kundu, and Zhenghua Zhu*. Gas-propelled nanomotors alleviate colitis through the regulation of intestinal immunoenvironment-hematopexis-microbiota circuits. Acta Pharm. Sin. B 2023, Just Accepted. (IF = 14.5） 3. Lingli Ma, Ya Ma, Qiang Gao, Shengsheng Liu, Zhenhua Zhu, Xiaoxiao Shi, Fangyin Dai*, Rui L. Reis, Subhas C. Kundu, Kaiyong Cai*, and Bo Xiao*. Mulberry Leaf Lipid Nanoparticles: A Naturally Targeted CRISPR/Cas9 Oral Delivery Platform for Alleviation of Colon Diseases. Small, Just Accepted.（IF = 13.3） 4. Jiaxue Wu, Shixiong Yi, Yingui Cao, Menghang Zu, Baoyi Li, Wenjing Yang, Mohammad-Ali Shahbazi, Rui L. Reis, Subhas C. Kundu, Xiaoxiao Shi,* and Bo Xiao*. Dual-driven nanomotors enable tumor penetration and hypoxia alleviation for calcium overload-photo-immunotherapy against colorectal cancer. Biomaterials 2023;302:122332. (IF = 13.9) 5. Wenjing Yang, Ya Ma, Haiting Xu, Zhenhua Zhu, Jiaxue Wu, Cheng Xu, Wei Sun, Erhu Zhao, Min Wang*, Rui L. Reis, Subhas C. Kundu, Xiaoxiao Shi*, and Bo Xiao*. Mulberry Biomass-Derived Nanomedicines Mitigate Colitis through Improved Inflamed Mucosa Accumulation and Intestinal Microenvironment Modulation. Research 2023;6:0188. (IF = 11.0） 6. Qiubing Chen, Menghang Zu, Hanlin Gong, Ya Ma, Jianfeng Sun, Susan Ran, Xiaoxiao Shi, Jinming Zhang* and Bo Xiao*. Tea leaf？derived exosome？like nanotherapeutics retard breast tumor growth by pro？apoptosis and microbiota modulation. Journal of Nanobiotechnology 2023;21:6. (IF = 10.2） 7. Jiming Xu, Wei Qiu, Mengyun Liang, Mengjie Ye, Junfeng Hu, Xianbin Ma, Xiaoxiao Shi, Peng Xue, Yuejun Kang, Bo Xiao*, Zhigang Xu*. Dual-stimulus phototherapeutic nanogel for triggering pyroptosis to promote cancer immunotherapy. Journal of Controlled Release 2023;358:219. （IF = 10.7） 8. Yingui Cao, Shengsheng Liu, Ya Ma, Lingli Ma, Menghang Zu, Jianfeng Sun, Fangyin Dai, Lian Duan*, and Bo Xiao*. Oral Nanomotor-Enabled Mucus Traverse and Tumor Penetration for Targeted Chemo-Sono-Immunotherapy against Colon Cancer. Small 2022; 2203466. (IF = 13.3) 9. Ya Ma, Lian Duan, Jianfeng Sun, Shuangquan Gou, Fengyuan Chen, Yuqi Liang, Fangyin Dai, Bo Xiao*. Oral nanotherapeutics based on Antheraea pernyi silk fibroin for synergistic treatment of ulcerative colitis. Biomaterials 2022;282: 21410.（IF = 13.9） 10. Shuangquan Gou, Nanxi Chen, Xiaoai Wu, Menghang Zu, Shixiong Yi, Binwu Ying*, Fangyin Dai, Bowen Ke*, Bo Xiao*. Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapy. Acta Pharm. Sin. B 2022;12(1):406-423. (IF = 14.5） 11. Chen Q., Li Q., Liang Y., Zu M., Chen N., Canup B., Luo L., Wang C.*, Zeng L.*, and Xiao B.* Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation. Acta Pharm. Sin. B 2022;12(2):907-923. (IF = 14.5） 12. Shengsheng Liu, Yingui Cao, Lingli Ma, Jianfeng Sun, Lorenzo Ramos-Mucci, Ya Ma, Xiao Yang, Zhenhua Zhu, Jianxiang Zhang, and Bo Xiao*. Oral antimicrobial peptide-EGCG nanomedicines for synergistic treatment of ulcerative colitis. Journal of Controlled Release 2022;347:544–560. （IF = 10.7） 13. Xueqing Zhang, Qian He, Jianfeng Sun, Hanlin Gong, Yingui Cao, Lian Duan, Shixiong Yi,* Binwu Ying,* and Bo Xiao*. Near-Infrared-Enpowered Nanomotor-Mediated Targeted Chemotherapy and Mitochondrial Phototherapy to Boost Systematic Antitumor Immunity. Advanced Healthcare Materials 2022; 2200255.（IF = 9.9） 14. Menghang Zu, Dengchao Xie, Brandon S.B. Canup, Nanxi Chen, Yajun Wang, Ruxin Sun, Zhan Zhang, Yuming Fu,* Fangyin Dai,* and Bo Xiao*. ‘Green’ nanotherapeutics from tea leaves for orally targeted prevention and alleviation of colon diseases. Biomaterials 2021; 279: 121178. （IF = 13.9） 15. Zu M., Ma Y., Cannup B., Xie D., Jung Y., Zhang J., Yang C., Gao F.*, Merlin D.*, and Xiao B.*. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv. Drug Deliv. Rev. 2021;176:113887. (IF = 16.1） 16. Zhang X., Huang Y., Song H., Canup B.S.B., Gou S., She Z., Dai F.*, Ke B.*, and Xiao B.*. Inhibition of growth and lung metastasis of breast cancer by tumor-homing triple-bioresponsive nanotherapeutics. Journal of Controlled Release 2020;328:454-469. （IF = 10.7） 17. Gou S., Yang J., Ma Y., Zhang X., Zu M., Kang T., Liu S., Ke B.*, and Xiao B.*. Multi-responsive nanococktails with programmable targeting capacity for imaging-guided mitochondrial phototherapy combined with chemotherapy. Journal of Controlled Release 2020;327: 371-383. （IF = 10.7） 18. Gou S., Huang Y., Wan Y., Ma Y., Zhou X., Tong X., Huang J.*, Kang Y.*, Pan G., Dai F., and Xiao B.*. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials 2019; 212:39-54. （IF = 13.9） 19. Xiao B.*, Viennois E., Chen Q., Wang L., Han M., Zhang Y., Zhang Z., Kang Y., Wan Y., and Merlin D.. Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer. ACS nano 2018;12:5253-5265.（IF = 17.9） 20. Xiao B*, Chen Q, Zhang Z, Wang L, Denning T, Kang Y, and Merlin D. TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis. Journal of Controlled Release 2018;287:235-246.（IF = 10.7） 21. Xiao B.*, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy 2017;25(5):1628-1640. （Cell子刊， IF = 12.4） 22. Xiao B.*, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK, Chen J, Merlin D. Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation. Theranostics 2016;6:2250-66.（IF = 12.4） 23. Xiao B.*, Zhang M., Viennois E., Zhang Y., Wei N., Baker M.T., Jung Y., Merlin D. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials 2015;48:147-160.（IF = 13.9） 24. Xiao B.*, Laroui H., Viennois E., Ayyadurai S., Charania M.A., Zhang Y., Zhang Z., Baker M.T., Zhang B., Gewirtz A.T., and Merlin D.. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 2014; 146(5):1289-1300.（IF = 29.4） 25. Xiao B.*, Laroui H., Ayyadurai H., Viennois E., Charania M.A., Zhang Y., Merlin D.. Mannosylated bioreducible nanoparticle-mediated macrophage-speci？c TNF-α RNA interference for IBD therapy. Biomaterials 2013;34(30):7471-82. （直接接收，IF = 13.9） 专业研究方向： 专业名称 研究领域/方向 招生类别 107200生物医学工程 04药学 博士学术学位 071000生物学 01生物化学与分子生物学 硕士学术学位 105500药学 02药物研究与转化 硕士专业学位 学院列表 01 信息与通信工程学院 02 电子科学与工程学院 03 材料与能源学院 04 机械与电气工程学院 05 光电科学与工程学院 06 自动化工程学院 07 资源与环境学院 08 计算机科学与工程学院（网络空间安全学院） 09 信息与软件工程学院（示范性软件学院） 10 航空航天学院 11 数学科学学院 12 物理学院 13 医学院 14 生命科学与技术学院 15 经济与管理学院 16 公共管理学院 17 外国语学院 18 马克思主义学院 21 基础与前沿研究院 22 通信抗干扰全国重点实验室 23 电子科学技术研究院 28 电子科技大学（深圳）高等研究院 31 集成电路科学与工程学院（示范性微电子学院） 90 智能计算研究院 (责任编辑：) |